XENE Xenon Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1582313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-40.0%
TTM EPS YoY-20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-50.3%
ROA-47.4%
ROIC (approx.)-48.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio21.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.50M | $0 |
| R&D expense | $300.94M | $210.39M |
| SG&A expense | $79.63M | $68.90M |
| Operating income | -$373.07M | -$279.30M |
| Pretax income | -$344.89M | -$238.42M |
| Income tax | $1.02M | -$4.09M |
| Net income | -$345.91M | -$234.33M |
| EBITDA | -$370.53M | -$276.74M |
| EPS (basic) | -4.36 | -3.01 |
| EPS (diluted) | -4.36 | -3.01 |
| Weighted avg. shares (diluted) | 79.25M | 77.89M |
| Balance sheet | ||
| Cash & equivalents | $199.16M | $142.71M |
| Short-term investments | $349.72M | $484.19M |
| Receivables | — | $1.47M |
| Current assets | $560.65M | $635.26M |
| PP&E, net | $8.72M | $10.28M |
| Total assets | $633.16M | $798.14M |
| Current liabilities | $41.79M | $35.59M |
| Total liabilities | $51.40M | $43.24M |
| Shareholders' equity | $581.76M | $754.90M |
| Shares outstanding | 80.01M | 76.42M |
| Cash flow statement | ||
| Operating cash flow | -$279.12M | -$181.39M |
| Capital expenditure | $799,000 | $3.08M |
| Free cash flow | -$279.92M | -$184.46M |
| Investing cash flow | $218.00M | $165.00M |
| Financing cash flow | $117.11M | $12.13M |
| Depreciation & amortization | $2.54M | $2.56M |
| Stock-based compensation | $53.71M | $50.72M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.